Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de etiqueta abierta para evaluar la seguridad y eficacia de CABA-201 en sujetos con miopatía inflamatoria idiopática activa

12 de noviembre de 2026 actualizado por: Cabaletta Bio

Un estudio abierto de fase 1/2 para evaluar la seguridad y eficacia de las células T autólogas del receptor de antígeno quimérico específico de CD19 (CABA-201) en sujetos con miopatía inflamatoria idiopática activa

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

74

Fase

  • Fase 2
  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Göttingen, Alemania, 37075
        • Aún no reclutando
        • Universitätsmedizin Göttingen - Accepting Adult Patients
        • Contacto:
        • Investigador principal:
          • Dr. Jana Zschüntzsch
    • California
      • Orange, California, Estados Unidos, 92868
        • Reclutamiento
        • University of California Irvine - Accepting Adult Patients
        • Investigador principal:
          • Tahseen Mozaffar, MD
        • Contacto:
      • San Francisco, California, Estados Unidos, 94158
        • Reclutamiento
        • University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
        • Contacto:
        • Investigador principal:
          • Susan Kim, MD, MMSc
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80046
        • Reclutamiento
        • Children's Hospital Colorado - Accepting Juvenile Patients
        • Investigador principal:
          • Dr. Kentaro Yomogida, MD
        • Contacto:
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32224
        • Reclutamiento
        • Mayo Clinic Florida - Accepting Adult Patients
        • Contacto:
      • St. Petersburg, Florida, Estados Unidos, 33701
        • Reclutamiento
        • Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
        • Investigador principal:
          • Natalie Booth, DO
        • Contacto:
          • Laura Escobar
          • Número de teléfono: 727-767-2946
          • Correo electrónico: llabarr2@jh.edu
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30032
        • Reclutamiento
        • Emory University - Accepting Adult Patients
        • Contacto:
        • Investigador principal:
          • Prateek Chandrashekar Gandiga, MD, FACP
      • Atlanta, Georgia, Estados Unidos, 30029
        • Reclutamiento
        • Children's Healthcare of Atlanta - Accepting Juvenile Patients
        • Investigador principal:
          • Shanmuganathan Chandrakasan, MD
        • Contacto:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Reclutamiento
        • Northwestern Memorial Hospital - Accepting Adult Patients
        • Investigador principal:
          • Dr. George Georges, MD
        • Contacto:
      • Chicago, Illinois, Estados Unidos, 60637
      • Chicago, Illinois, Estados Unidos, 60611
        • Reclutamiento
        • Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
        • Contacto:
        • Investigador principal:
          • Pooja N. Patel, DO
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Reclutamiento
        • University of Kansas Medical Center - Accepting Adult Patients
        • Contacto:
          • Samantha Colgan
          • Número de teléfono: 913-945-9938
          • Correo electrónico: scolgan@kumc.edu
    • Maryland
      • Bethesda, Maryland, Estados Unidos, 20892
        • Reclutamiento
        • National Institutes of Health - Accepting Adult and Juvenile Patients
        • Contacto:
        • Investigador principal:
          • Andrew Mammen, M.D., Ph.D.
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Reclutamiento
        • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
        • Investigador principal:
          • Susan Prockop, MD
        • Contacto:
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48105
        • Reclutamiento
        • University of Michigan - Accepting Young Adult and Juvenile Patients
        • Contacto:
        • Investigador principal:
          • Dr. Jennifer Agrusa, MD
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55902
        • Reclutamiento
        • Mayo Clinic - Accepting Adult Patients
        • Contacto:
    • New York
      • New York, New York, Estados Unidos, 10021
        • Reclutamiento
        • Hospital for Special Surgery - Accepting Adult and Juvenile Patients
        • Contacto:
          • Janvi Bhatia
          • Número de teléfono: 212-774-2123
          • Correo electrónico: bhatiaj@hss.edu
        • Investigador principal:
          • David R. Fernandez, MD, PhD
      • New York, New York, Estados Unidos, 10021
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
        • Investigador principal:
          • Jae Park, MD
        • Contacto:
          • Atifah Osrat
          • Número de teléfono: 646-608-2091
          • Correo electrónico: osrata1@mskcc.org
      • The Bronx, New York, Estados Unidos, 10467
        • Reclutamiento
        • Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
        • Contacto:
        • Investigador principal:
          • Dr. Dawn Wahezi, MD, MS
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • Reclutamiento
        • University of North Carolina at Chapel Hill - Accepting Adult Patients
        • Investigador principal:
          • Saira Sheikh, MD
        • Contacto:
      • Durham, North Carolina, Estados Unidos, 27710
        • Reclutamiento
        • Duke University Medical Center - Accepting Young Adults and Juvenile Patients
        • Investigador principal:
          • Kaveh Ardalan, MD, MS
        • Contacto:
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239
        • Reclutamiento
        • Oregon Health & Science University - Accepting Adult Patients
        • Contacto:
          • Katie Lewis
          • Número de teléfono: 503-908-9724
          • Correo electrónico: lewiskat@ohsu.edu
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Reclutamiento
        • Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
        • Contacto:
        • Investigador principal:
          • Dr. Caitlin Elgarten, MD, MSCE
      • Pittsburgh, Pennsylvania, Estados Unidos, 15261
        • Reclutamiento
        • UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
        • Contacto:
        • Investigador principal:
          • Jeremy Tilstra, MD
      • Pittsburgh, Pennsylvania, Estados Unidos, 15224
        • Reclutamiento
        • UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
        • Contacto:
        • Investigador principal:
          • Kathryn Torok, MD
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Reclutamiento
        • Vanderbilt University Medical Center - Accepting Adult Patients
        • Contacto:
    • Texas
      • Dallas, Texas, Estados Unidos, 75390
        • Reclutamiento
        • University of Texas Southwestern Medical Center - Accepting Juvenile Patients
        • Investigador principal:
          • Samuel John, MD
        • Contacto:
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • Houston Methodist Hospital - Accepting Adult Patients
        • Contacto:
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • University of Texas MD Anderson Cancer Center - Accepting Adult Patients
        • Investigador principal:
          • Huifang (Linda) Lu, MD
        • Contacto:
          • Christina Amos Briggs, BSN, RN
          • Número de teléfono: 713-563-5076
          • Correo electrónico: cbamos@mdanderson.org
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84113
        • Reclutamiento
        • Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
        • Contacto:
        • Investigador principal:
          • Aimee Ogden Hersh, MD
    • Washington
      • Seattle, Washington, Estados Unidos, 98105
        • Reclutamiento
        • Seattle Children's Research Institute - Accepting Juvenile Patients
        • Contacto:
        • Investigador principal:
          • Dr. Susan Shenoi, MD, MS
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Aún no reclutando
        • Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
        • Investigador principal:
          • Sara Sabbagh, DO
        • Contacto:
          • Erin Hammelev - Research Coordinator
          • Número de teléfono: 414-337-7064
          • Correo electrónico: ehammele@mcw.edu
      • Roma, Italia, 00165
        • Reclutamiento
        • Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
        • Contacto:
        • Investigador principal:
          • Professor Franco Locatelli
      • London, Reino Unido, WC1N 3BG
        • Reclutamiento
        • University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
        • Contacto:
        • Investigador principal:
          • Dr. Pedro Machado, FRCP, PhD
      • London, Reino Unido, SE5 9RS
        • Reclutamiento
        • Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
        • Contacto:
        • Investigador principal:
          • Patrick Gordon, PhD, FRCP, MBBS
      • London, Reino Unido, WC1N 3JH
        • Reclutamiento
        • Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
        • Contacto:
        • Investigador principal:
          • Professor Despina Eleftheriou
      • Manchester, Reino Unido, M13 9WL
        • Reclutamiento
        • Manchester Royal Infirmary - Accepting Adult Patients
        • Contacto:
          • Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
          • Número de teléfono: 01612765052
          • Correo electrónico: Eleni.Tholouli@mft.nhs.uk
        • Investigador principal:
          • Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
      • Salford, Reino Unido, M6 8HD
        • Reclutamiento
        • Salford Royal Hospital - Accepting Adult Patients
        • Contacto:
        • Investigador principal:
          • Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

6 años a 75 años (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Adult Cohorts

Inclusion Criteria:

  • Age ≥18 and ≤75
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Diagnosis of DM, ASyS, or IMNM
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
  • Presence of muscle weakness

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Juvenile Cohort

Inclusion Criteria:

  • Age ≥6 and ≤17 years at enrollment
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: CABA-201 Phase 1/2

DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM.

ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS.

IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Otros nombres:
  • Reseir
  • Resecabtagene Autoleucel
Experimental: CABA-201 Phase 2b - Sub-study 1

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Otros nombres:
  • Reseir
  • Resecabtagene Autoleucel
Experimental: CABA-201 Phase 2b - Sub-study 2

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Otros nombres:
  • Reseir
  • Resecabtagene Autoleucel

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Phase 1/2: Incidence and severity of adverse events (AEs)
Periodo de tiempo: Up to 28 days after CABA-201 infusion

Incidence and severity of AEs

Up to 28 days after CABA-201 infusion
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Within 16 weeks

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 16 weeks
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Within 24 weeks

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 24 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of adverse events and laboratory abnormalities
Periodo de tiempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Incidence and severity of AEs, including changes in laboratory values and vital signs

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacodynamics (PD)
Periodo de tiempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of B cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacokinetics (PK)
Periodo de tiempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of CABA-201-positive T cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Change in disease-related biomarkers of muscle inflammation
Periodo de tiempo: Up to 156 weeks (Phase 1/2)

Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum

Up to 156 weeks (Phase 1/2)
Change in autoantibody-related biomarkers
Periodo de tiempo: Up to 156 weeks (Phase 1/2)

Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum

Up to 156 weeks (Phase 1/2)
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Week 16 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Week 16 (Sub-study 1)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 16 (Sub-study 1)
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Week 16 (Sub-study 1)

≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Periodo de tiempo: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Periodo de tiempo: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Week 24 (Sub-study 2)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 24 (Sub-study 2)
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Periodo de tiempo: Week 52 (Sub-study 2)

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 2)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: Medical Director, Cabaletta Bio

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

20 de diciembre de 2023

Finalización primaria (Estimado)

1 de julio de 2028

Finalización del estudio (Estimado)

1 de julio de 2028

Fechas de registro del estudio

Enviado por primera vez

16 de noviembre de 2023

Primero enviado que cumplió con los criterios de control de calidad

30 de noviembre de 2023

Publicado por primera vez (Actual)

4 de diciembre de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .